Daryll M. Baker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daryll M. Baker has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ayyaz Quddus
Royal Free London Hospital , London, United Kingdom
1 shared publication - Borzoueh Mohammadi
Department of Upper Gastro-Intestinal Surgery, University College London Hospitals NHS Foundation Trust, London, UK
1 shared publication - Geoffrey Chow
Royal Free London NHS Foundation Trust
1 shared publication - Julian Hague
University College London Hospitals NHS Foundation Trust , London , United Kingdom
1 shared publication - Khaled Dawas
Department of Upper Gastro-Intestinal Surgery, University College London Hospitals NHS Foundation Trust, London, UK
1 shared publication L. Cruddas
University College London Medical School, London, UK
1 shared publication
Latest Publications
- 4 June 2024
- Published by Springer Nature
- p. 149-155
Chemotherapy Emboli as an Iatrogenic Cause of Ischaemic Stroke Arising from a Misplaced Central Venous Access Line
- 4 June 2024
- Published by Springer Nature
- p. 149-155
Chemotherapy Emboli as an Iatrogenic Cause of Ischaemic Stroke Arising from a Misplaced Central Venous Access Line
- Open Access
- 1 March 2021
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2021 (3) , rjab035
Dual-modality emergency management of a rare cause of an aorto-oesophageal fistula: a case report
Aorto-oesophageal fistula (AOF) is a life-threatening condition that usually presents with upper gastro-intestinal haemorrhage. This case report details the emergency presentation and management of a 51-year-old male who presented with hematemesis secondary to an impacted denture (ingested two years previously) in the oesophagus that had led to an AOF. This necessitated urgent thoracic endovascular aortic repair followed by thoracotomy, oesophagotomy, T-tube insertion and oesophagostomy. This is the first documentation in the literature of the dual-modality management for this rare cause of AOF and demonstrates the multidisciplinary approach to successful management of this complex yet rare presentation.
- 1 March 2021
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2021 (3) , rjab035
Open AccessDual-modality emergency management of a rare cause of an aorto-oesophageal fistula: a case report
Aorto-oesophageal fistula (AOF) is a life-threatening condition that usually presents with upper gastro-intestinal haemorrhage. This case report details the emergency presentation and management of a 51-year-old male who presented with hematemesis secondary to an impacted denture (ingested two years previously) in the oesophagus that had led to an AOF. This necessitated urgent thoracic endovascular aortic repair followed by thoracotomy, oesophagotomy, T-tube insertion and oesophagostomy. This is the first documentation in the literature of the dual-modality management for this rare cause of AOF and demonstrates the multidisciplinary approach to successful management of this complex yet rare presentation.
- Open Access
- 22 June 2020
- Published by Heighten Science Publications Corporation in Heighpubs Otolaryngology and Rhinology
- Vol. 4 (1) , 006-007
Why are more otorhinolaryngology surgeons dying from Covid-19 than any other surgical specialty?
Covid-19 infection is caused by the coronavirus SARS-CoV-2.
- 22 June 2020
- Published by Heighten Science Publications Corporation in Heighpubs Otolaryngology and Rhinology
- Vol. 4 (1) , 006-007
Open AccessWhy are more otorhinolaryngology surgeons dying from Covid-19 than any other surgical specialty?
Covid-19 infection is caused by the coronavirus SARS-CoV-2.
- 21 February 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (6) , 952-963
Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review
Primary hyperhidrosis is a condition characterized by excessive sweating. Patients are treated off‐license with oral anticholinergic medications and report adverse events associated with systemic anticholinergic interactions. This review assesses clinical evidence of efficacy, impact on quality of life and adverse events associated with oral anticholinergic therapy for primary hyperhidrosis. PRISMA guidelines were implemented to complete a systematic review (PROSPERO:CRD42016036326). MEDLINE, EMBASE and PubMed were searched from 1946 to 2015. Inclusion criteria included observational and experimental studies, anticholinergic medication use in primary hyperhidrosis, oral therapy and clear diagnostic and outcome measures. Twenty‐three articles relevant to the inclusion criteria were analysed. Oxybutynin therapy improved symptoms in an average of 76.2% (range 60–97%) patients and improved QOL in 75.6% (range 57.6–100%) of patients. Methantheline bromide therapy was associated with a 41% reduction in axillary sweating, 16.4% reduction in palmar sweating, 25% decrease in HDSS score and 40.9% increase in DLQI score. Outcome measures of glycopyrrolate therapy were too variable to collate. Dry mouth was reported in 73.4% (range 43.3–100%) of participants taking oxybutynin 10 mg/day, 38.6% (range 27.8–63.2%) of patients taking glycopyrrolate and 68.8% of patients taking methantheline bromide. Nine studies reported that patients stopped therapy due to adverse events. In eight of these studies, a mean of 10.9% of total participants ceased treatment due to dry mouth. Evidence of oral anticholinergic therapy for hyperhidrosis is limited. However, its use is associated with improvement in quality of life and clinical symptoms but at the cost of considerable adverse events.
- 21 February 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (6) , 952-963
Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review
Primary hyperhidrosis is a condition characterized by excessive sweating. Patients are treated off‐license with oral anticholinergic medications and report adverse events associated with systemic anticholinergic interactions. This review assesses clinical evidence of efficacy, impact on quality of life and adverse events associated with oral anticholinergic therapy for primary hyperhidrosis. PRISMA guidelines were implemented to complete a systematic review (PROSPERO:CRD42016036326). MEDLINE, EMBASE and PubMed were searched from 1946 to 2015. Inclusion criteria included observational and experimental studies, anticholinergic medication use in primary hyperhidrosis, oral therapy and clear diagnostic and outcome measures. Twenty‐three articles relevant to the inclusion criteria were analysed. Oxybutynin therapy improved symptoms in an average of 76.2% (range 60–97%) patients and improved QOL in 75.6% (range 57.6–100%) of patients. Methantheline bromide therapy was associated with a 41% reduction in axillary sweating, 16.4% reduction in palmar sweating, 25% decrease in HDSS score and 40.9% increase in DLQI score. Outcome measures of glycopyrrolate therapy were too variable to collate. Dry mouth was reported in 73.4% (range 43.3–100%) of participants taking oxybutynin 10 mg/day, 38.6% (range 27.8–63.2%) of patients taking glycopyrrolate and 68.8% of patients taking methantheline bromide. Nine studies reported that patients stopped therapy due to adverse events. In eight of these studies, a mean of 10.9% of total participants ceased treatment due to dry mouth. Evidence of oral anticholinergic therapy for hyperhidrosis is limited. However, its use is associated with improvement in quality of life and clinical symptoms but at the cost of considerable adverse events.
- 13 July 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (12) , 2131-2136
Topical glycopyrrolate reduces axillary hyperhidrosis
Introduction: Oral anti‐cholinergic medications reduce generalized hyperhidrosis, but the effectiveness of topical anticholinergic solutions on axillary hyperhidrosis is unclear. This study determines the initial effectiveness of 1% and 2% topical glycopyrrolate spray and compares this with Botulinum toxin type A injections for the management of axillary hyperhidrosis.Methods: In a non‐randomized, consecutive patient, prospective questionnaire, treatment comparison study, 40 patients with axillary hyperhidrosis were allocated to one of four study groups (10 patients to each group): (a) 1% glycopyrrolate spray, (b) 2% glycopyrrolate spray, (c) subcutaneous Botulinum toxin type A injections, (d) no treatment. Clinical outcomes were measured by comparing a prospectively administered questionnaire, completed both pre‐treatment and 6 weeks after starting treatment. Forty healthy volunteers without axillary hyperhidrosis completed the same questionnaire.Results: The three treatment groups showed a significant (P < 0.05) improvement in their hyperhidrosis scores following treatment. The degree of improvement was less for the 1% glycopyrrolate group when compared with the Botulinum toxin type A group (P < 0.05), but there was no difference in treatment outcomes between the 2% glycopyrrolate and Botulinum toxin type A groups. No treatment group experienced reduced hyperhidrosis to a level similar to those without hyperhidrosis. Patients in both, the 2% glycopyrrolate and Botulinum toxin type A groups reported a significant improvement in axillary hyperhidrosis symptoms. These included reduction in psychologically precipitating factors (e.g. public speaking) and axillary hyperhidrosis‐specific physical effects (e.g. limitation of clothing choice).Conclusions: Topical glycopyrrolate spray could provide a further treatment modality to manage axillary hyperhidrosis.
- 13 July 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (12) , 2131-2136
Topical glycopyrrolate reduces axillary hyperhidrosis
Introduction: Oral anti‐cholinergic medications reduce generalized hyperhidrosis, but the effectiveness of topical anticholinergic solutions on axillary hyperhidrosis is unclear. This study determines the initial effectiveness of 1% and 2% topical glycopyrrolate spray and compares this with Botulinum toxin type A injections for the management of axillary hyperhidrosis.Methods: In a non‐randomized, consecutive patient, prospective questionnaire, treatment comparison study, 40 patients with axillary hyperhidrosis were allocated to one of four study groups (10 patients to each group): (a) 1% glycopyrrolate spray, (b) 2% glycopyrrolate spray, (c) subcutaneous Botulinum toxin type A injections, (d) no treatment. Clinical outcomes were measured by comparing a prospectively administered questionnaire, completed both pre‐treatment and 6 weeks after starting treatment. Forty healthy volunteers without axillary hyperhidrosis completed the same questionnaire.Results: The three treatment groups showed a significant (P < 0.05) improvement in their hyperhidrosis scores following treatment. The degree of improvement was less for the 1% glycopyrrolate group when compared with the Botulinum toxin type A group (P < 0.05), but there was no difference in treatment outcomes between the 2% glycopyrrolate and Botulinum toxin type A groups. No treatment group experienced reduced hyperhidrosis to a level similar to those without hyperhidrosis. Patients in both, the 2% glycopyrrolate and Botulinum toxin type A groups reported a significant improvement in axillary hyperhidrosis symptoms. These included reduction in psychologically precipitating factors (e.g. public speaking) and axillary hyperhidrosis‐specific physical effects (e.g. limitation of clothing choice).Conclusions: Topical glycopyrrolate spray could provide a further treatment modality to manage axillary hyperhidrosis.
- 9 June 2015
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 16 (5) , 361-370
Treatment of Primary Craniofacial Hyperhidrosis: A Systematic Review
Primary craniofacial hyperhidrosis (CH) can have a profoundly negative impact on quality of life. No comprehensive review of its management exists. The objective of this review is to present the best clinical evidence to guide CH management. A systematic review was performed using PRISMA guidelines. MEDLINE and EMBASE were searched from 1966 to 2014 for articles using the MeSH terms “Hyperhidrosis”, “Head”, “Neck” and synonymous text words. Inclusion criteria were experimental and observational studies addressing CH treatment. Two reviewers independently assessed study quality and analysed data. Of 833 references yielded, 27 met inclusion criteria and were analysed. Twenty-two studies evaluated T2 sympathetic ablation (Level III evidence). Outcome measures were subjective and mean follow-up was 29 months. Reported efficacy was high (70–100 %), recurrence rates were generally low (0–8 %) and complications largely transient (e.g. pneumothorax 0–1 %). However, 8–95.4 % experienced troubling compensatory sweating. One randomised controlled trial and one observational study evaluated botulinum toxin A (Level Ib and III, respectively). Both employed objective outcome measures and demonstrated similar findings. Efficacy was 100 %, lasted a median of 5–6 months and frontalis muscle inhibition was the main adverse effect (50–100 %). Three studies evaluated anticholinergic therapy: topical glycopyrrolate demonstrated high efficacy (96 %) with minimal adverse effects (Level Ib) and oral oxybutynin demonstrated relatively high efficacy (80–100 %) but with noticeable adverse effects (76.6–83.6 %) (Level III). There are few quality studies evaluating CH treatment. Based on available evidence, we recommend topical glycopyrrolate, oral oxybutynin and intradermal botulinum toxin A as first-line therapies due to their efficacy and safety. T2 sympathectomy should be considered for patients refractory to first-line therapy.
- 9 June 2015
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 16 (5) , 361-370
Treatment of Primary Craniofacial Hyperhidrosis: A Systematic Review
Primary craniofacial hyperhidrosis (CH) can have a profoundly negative impact on quality of life. No comprehensive review of its management exists. The objective of this review is to present the best clinical evidence to guide CH management. A systematic review was performed using PRISMA guidelines. MEDLINE and EMBASE were searched from 1966 to 2014 for articles using the MeSH terms “Hyperhidrosis”, “Head”, “Neck” and synonymous text words. Inclusion criteria were experimental and observational studies addressing CH treatment. Two reviewers independently assessed study quality and analysed data. Of 833 references yielded, 27 met inclusion criteria and were analysed. Twenty-two studies evaluated T2 sympathetic ablation (Level III evidence). Outcome measures were subjective and mean follow-up was 29 months. Reported efficacy was high (70–100 %), recurrence rates were generally low (0–8 %) and complications largely transient (e.g. pneumothorax 0–1 %). However, 8–95.4 % experienced troubling compensatory sweating. One randomised controlled trial and one observational study evaluated botulinum toxin A (Level Ib and III, respectively). Both employed objective outcome measures and demonstrated similar findings. Efficacy was 100 %, lasted a median of 5–6 months and frontalis muscle inhibition was the main adverse effect (50–100 %). Three studies evaluated anticholinergic therapy: topical glycopyrrolate demonstrated high efficacy (96 %) with minimal adverse effects (Level Ib) and oral oxybutynin demonstrated relatively high efficacy (80–100 %) but with noticeable adverse effects (76.6–83.6 %) (Level III). There are few quality studies evaluating CH treatment. Based on available evidence, we recommend topical glycopyrrolate, oral oxybutynin and intradermal botulinum toxin A as first-line therapies due to their efficacy and safety. T2 sympathectomy should be considered for patients refractory to first-line therapy.